Our data implies that mTORC1 inhibitor therapies are unlikely to restore inflammation in TSC, raising the possibility that NF-κB dysregulation could contribute to the failure of current mTORC1 inhibitors to completely ablate TSC symptoms [10]. The gene discussed is NFKB1; the disease is tuberous sclerosis.